Organigram's Promising Results From Nanoemulsion Technology Study To Improve Cannabis Edibles
Portfolio Pulse from Rolando García
Organigram Holdings Inc. (NASDAQ:OGI) announced promising preliminary results from a clinical study on their new nanoemulsion technology, branded FAST. The study showed faster onset of effects and improved bioavailability for cannabis edibles. Organigram plans to commercialize FAST in fall 2024, starting with gummies.

August 08, 2024 | 4:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Organigram Holdings Inc. announced promising results from a clinical study on their new nanoemulsion technology, FAST, which showed faster onset and improved bioavailability for cannabis edibles. The company plans to commercialize this technology in fall 2024.
The promising results from the clinical study on Organigram's nanoemulsion technology, FAST, indicate potential for significant advancements in their cannabis edibles products. The faster onset and improved bioavailability could attract more consumers, boosting sales and revenues. The planned commercialization in fall 2024 further supports a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100